RecruitingPhase 3NCT07734311

A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Ecnoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

Sponsor

Hangzhou Sciwind Biosciences Co., Ltd.

Enrollment

360 participants

Start Date

Aug 3, 2026

Study Type

INTERVENTIONAL

Conditions

Obesity Knee Osteoarthritis

Summary

The main purpose of the study is to evaluate the efficacy and safety of ecnoglutide injections versus placebo in obese participants with KOA.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ecnoglutide Injection and a drug called placebo with matching volume for people with knee osteoarthritis and obesity. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEcnoglutide Injection

subcutaneous injection

DRUGplacebo with matching volume

subcutaneous injection

Locations(1)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07734311

Related Trials

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

NCT060449351 location

Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study

NCT067301132 locations

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

NCT07752979

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT07743463

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459628 locations